Polygenic Risk Scores for Heart Disease: What They Add—and What They Cannot Replace

A polygenic risk score (PRS) combines information from many common DNA variants to estimate a person’s inherited susceptibility to a condition such as coronary artery disease. It is not a diagnosis, and it does not tell an individual whether a heart attack will occur. For people considering advanced preventive testing, the useful question is not simply whether a genetic score is high. It is whether the result changes a decision that improves care.

What is different about a polygenic risk score?

Most common cardiovascular diseases are influenced by many genes as well as blood pressure, cholesterol, diabetes, smoking, activity, diet and age. A PRS uses a statistical model to combine numerous genetic variants into a relative-risk estimate. Unlike a test for a specific inherited disorder, such as a pathogenic variant associated with familial hypercholesterolemia, a polygenic score generally does not establish a single-gene diagnosis.

Scores are often expressed as percentiles relative to a reference population. A high percentile means the score is higher than that of many people in that reference group; it does not mean a corresponding percentage chance of a heart attack. Absolute risk still depends heavily on clinical factors and the population in which the score was developed.

Why conventional cardiovascular assessment still comes first

The 2026 ACC/AHA multisociety dyslipidemia guideline emphasizes contemporary risk assessment using the PREVENT-ASCVD equations, lipid measurements, selected apolipoprotein B testing, lipoprotein(a) measurement and coronary artery calcium scoring in appropriate patients. These tools address established, actionable risks. For example, markedly elevated LDL cholesterol, high blood pressure or smoking calls for evaluation and management regardless of a reassuring genetic percentile.

A PRS may provide additional context for selected people, but it is not a replacement for a medical history, examination, lipid panel, family history or shared treatment decisions. A patient with a low genetic score can still develop significant atherosclerosis. Conversely, a higher score does not make disease inevitable.

Where genetic scores can mislead

Population transferability: A model developed primarily in one ancestry group may be less accurate in another. Laboratories vary in which variants they include, how scores are calibrated and what clinical interpretation they provide. Results from different providers may not be interchangeable.

False precision: A percentile looks exact even when its implications for a particular patient’s absolute risk are uncertain. A result may not meaningfully change whether a clinician recommends lifestyle changes, lipid-lowering medication or additional evaluation.

Confusion with monogenic disease: A polygenic score should not replace appropriate evaluation for familial hypercholesterolemia or other inherited conditions when clinical history suggests them. Very high LDL cholesterol or a strong family history of premature cardiovascular disease deserves attention independently of PRS.

Questions worth asking before ordering a score

Ask which condition is being predicted, which population validated the score, whether the report gives absolute risk or only relative rank, and what action would change because of the result. Also ask whether a clinician familiar with genetics will interpret findings and whether the laboratory provides transparent limitations. Genetic information can have privacy and family implications; patients should understand data handling before testing.

How an executive physical can use the broader picture

In a comprehensive preventive evaluation, a clinician may consider personal and family history, blood pressure, standard and advanced lipid measures, metabolic health and selected imaging together. Genetic information is most useful when it adds something actionable to that foundation. More testing is not automatically better testing.

Our cardiac and vascular testing and executive physical pages explain how individualized assessments are organized. For a separate discussion of sequencing and potentially actionable inherited findings, see our whole-genome sequencing service.

Bottom line

Polygenic scores are promising research and emerging clinical tools, but they should be interpreted in context. Decisions about prevention should continue to rest on validated clinical risk assessment, evidence-based treatments and individual preferences rather than a genetic percentile alone.

Medical references

1. American Heart Association: 2026 Guideline on the Management of Dyslipidemia (March 13, 2026).
2. ACC/AHA multisociety dyslipidemia guideline (2026), including discussion of polygenic risk scores.

Educational information only; not individualized medical advice. The potential clinical value of genetic testing depends on the patient and the test.

Medically reviewed by David Nazarian, MD on October 23, 2026